Tagged with M

Biofarma Turkey Mr Sözeri, Pharmaceutical Executive’s readers are keen to discover, through our reports, prominent industry personalities, and they like to hear their stories. You have an outstanding career, having worked for both international and local giants – Deva, Abdi Ibrahim, Actavis, Astra Zeneca…- Can you tell us a little bit more…

More Pharma Mexico There are about 250 employees and you have regional presence in Latin America. In your view as CEO, can you tell our readers about the biggest growth drivers and challenges in the Mexican pharmaceutical market since then? At More Pharma we believe we are navigating at an ever changing environment.…

Lundbeck Mexico You came back to Mexico last July- what in your view have been the biggest developments in the Mexican pharmaceutical market since you were last here 11 years ago? The last time I lived in Mexico was in 2002 when the pharmaceutical industry was growing strongly and most companies were…

Shire Pharmaceuticals Please can you give us a rundown of Shires activities in Mexico in the last four years, and the key achievements and milestones along the way? Shire started operations in Mexico in 2008, a similar story to Brazil. There are very few people working here in Shire Mexico but we…

Octapharma Mexico Please can you give our readers a brief rundown of the major milestones and challenges that you have faced at Octapharma since becoming Managing Director? When Octapharma first came to Mexico in 1994, it was through a distribution agreement with a local company. Six years later in the year 2000…

Cegedim Mexico From your perspective in healthcare consultancy at CEGEDIM, what do you think have been the most impactful changes in the Mexican pharmaceutical and healthcare sector over the last few years? One of the most important issues that changed in the Mexican pharmaceutical industry is the growth of generics, and this…

Latam Clinical Trials While LatAm originally emerged from the SIPLAS organization, how was it evolved since then to be where it is today? LatAm was born in 2000 as a business unit of SIPLAS labs and was known at the time as SIPLAS Research Organization. We decided to change our name to LatAm…

Hutchison Medipharma You began your career at Pfizer, working your way up the organizational ladder, when suddenly you decided to come to China back in 2001, well before China was on the map for R&D. What drove you to make this choice, to take the risk and come to China? It wasn’t…

Biotech Pharmaceutical Co Ltd Could you please introduce the history and main characteristics of Biotech Pharmaceutical? Biotech Pharmaceutical was established in the year 2000, so we are a relatively young company for biopharmaceutical products by Chinese standards. However, we were the first company in China to discover, develop, manufacture and market monoclonal antibodies. Before…

China Medicinal Biotech Association (CMBA) Could you please give us a brief introduction on CMBA? First and most obviously for new arrivals to our office, since 2011 we have changed locations, making it more convenient for companies to come here and benefit from the opportunities we can provide our members. CMBA’s membership now totals 205…

Genzyme (Shanghai) In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re now 30% closer to the deadline. How has this deep commitment to China resulted in developments in the country and…

Maver Maver has an impressive track record in developing and commercializing blockbuster products for the Chilean market, such as Tapsin and Disfruta, which today are the #1 brands in their categories. What would you say has been your recipe for success? I believe our success is based on our targeted marketing…